Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
This study has been completed.
Study NCT00782184 Information provided by Merck Sharp & Dohme Corp.
First Received on October 29, 2008. Last Updated on October 24, 2014
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Lipid Metabolism Disorders
Interventions listed in this trial
atorvastatin 40 mg
atorvastatin 20 mg
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers